Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinoma
Trial Details
- NCT ID
- NCT07239596
- Phase
- PHASE1 / PHASE2
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Kidney Cancer
- Interventions
- SHR-8068；Adebrelimab ；Bevacizumab
- SHR-8068；Adebrelimab ；HS-10516
- SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
- Age 18 to 75 years old (including boundary values)
- Volunteer to participate in this clinical study and sign informed consent;
- ECOG score 0-1;
- Expected survival ≥3 months;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →